Anakinra, an IL-1R antagonist, which was used to treat IL1+ pancreatic cancer tumor cells in mice combined with CAFs, reduced Th2 levels and improved overall survival of pancreatic cancer in a mouse model (Brunetto et al., 2019). Here, IL1R1 is linked to familial pancreatic carcinoma.